查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1819900

2025-2033年荷尔蒙避孕市场报告（依产品（口服避孕药、子宫内避孕器、注射避孕药、阴道环等）、荷尔蒙、年龄层、最终使用者和地区划分）

Hormonal Contraceptive Market Report by Product (Oral Contraceptive Pills, Intrauterine Device, Injectable Birth Control, Vaginal Rings, and Others), Hormone, Age Group, End User, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 142 Pages | 商品交期: 2-3个工作天内

价格

2024年，全球荷尔蒙避孕市场规模达194亿美元。展望未来， IMARC Group预计到2033年，该市场规模将达到268亿美元，2025-2033年期间的复合年增长率（CAGR）为3.48%。受全球生殖健康和计划生育意识的提升、妇女赋权（尤其是在发展中地区）的增强以及全球范围内避孕药具接受度和使用率的不断提高的推动，该市场正在稳步增长。

荷尔蒙避孕市场分析：

  • 主要市场驱动因素：全球范围内对计划生育的要求和接受度推动了荷尔蒙避孕药的需求。各国政府和非政府组织致力于降低意外怀孕率，这推动了该市场的成长。
  • 主要市场趋势：根据荷尔蒙避孕市场预测，最近对该市场产生重大影响的趋势是长效可逆避孕药（包括子宫内避孕器和植入物）的消费量不断增加，因为它们更有效、作用时间更长。
  • 地理趋势：北美和西欧由于较高的认知度、收入水平和医疗设施，在荷尔蒙避孕药的使用方面处于领先地位。相反，由于城市化、医疗支出和生活方式等因素，预计亚太地区将成长最快。
  • 竞争格局：根据荷尔蒙避孕药市场研究，荷尔蒙避孕药市场拥有多家大型製药公司，拥有广泛的产品组合和分销网络。无论大小公司都在增加研发预算，以开发副作用最小且方便消费者使用的新药。
  • 挑战与机会：虽然各个地理区域存在的文化阻力和监管障碍制约了市场成长，但仍有投资个人化避孕解决方案和关注女性就业增加的尚未解决的新兴市场的多个机会。

荷尔蒙避孕市场趋势：

提高全球对生殖健康的认识与教育

荷尔蒙避孕药在全球的广泛使用很大程度上取决于生殖健康意识和教育的提高。各国政府和世界卫生组织等相关国际组织不断推广透过安全有效的避孕措施进行计划生育的理念和优势。根据世界卫生组织统计，2021年全球育龄妇女数为19亿，其中11亿需要计划生育。其中，8.74亿人正在使用现代避孕方法，1.64亿女性的避孕需求尚未满足。因此，这极大地影响了荷尔蒙避孕药市场的收入。具体而言，全球范围内开展了广泛的宣传活动，面向男性和女性，告知他们控制怀孕的能力以及减少人口快速增长的有效方法。此外，也推出了许多针对青少年和年轻人的教育项目，为他们日后做出明智的计划生育决策奠定基础。这些教育措施只有在获得医疗保健服务和咨询的同时，才能有效发挥作用，使人们能够区分不同的荷尔蒙避孕方法。在这方面，全面的全球教育和健康计画对于确保这些产品在不同地区普及至关重要。

技术进步与产品创新

新型、更优的荷尔蒙避孕方案的开发彻底改变了这个领域，也推动了荷尔蒙避孕市场价值的提升。最近，一种新型超低剂量製剂（20 μg EE 和 3 mg DRSP）已上市，可24小时/4小时服用（Yaz；拜耳公司）。其疗效与旧式口服避孕药（COC）相似，甚至更佳，且出血情况可接受。此外，药物传输系统的开发正在带来更可靠、更易于管理且副作用更少的产品。延长週期避孕药和子宫内避孕器的改进（例如，更少的健康危害和更长的使用时间）都满足了消费者日益增长的便利性和生活方式兼容性的需求。此外，这些进步提升了消费者的体验和依从性，从而扩大了市场，因为女性更有可能使用和恢復避孕措施。此外，避孕产品技术的创新利用消费者的兴趣、采用和市场选择，推出了更精良的技术。因此，这为荷尔蒙避孕药市场创造了积极的前景。

计划生育政策措施和资金

政府推出的支持性政策和增加计划生育计画资金等政策促进了荷尔蒙避孕药市场的成长。一些地区，尤其是发展中国家的政府，已出台政策，确保个人能够获得避孕药具，并将其作为公共卫生和妇女赋权措施的一部分。这些政策降低了避孕药具的成本，使生殖健康服务更加全面，惠及所有人，并将避孕教育纳入公共卫生运动。此外，全球联盟和机构提供资金，帮助服务匮乏的地区获得生殖健康服务。所有这些措施都旨在降低成本，并鼓励人们使用避孕药。确保人们能够轻鬆低价获得荷尔蒙避孕药的政策有助于满足公共卫生需求和其他社会经济目标。

荷尔蒙避孕市场区隔：

按产品分类：

  • 口服避孕药
  • 子宫内避孕器（IUD）
  • 注射避孕药
  • 阴道环
  • 其他的

口服避孕药占据了荷尔蒙避孕药市场的大部分份额

口服避孕药 (OCP) 凭藉其无与伦比的功效、便利性和易得性，继续引领荷尔蒙避孕市场，成为最大的产品细分市场。荷尔蒙避孕市场概况表明，由于其安全性，避孕药是全球最常见的避孕方法，能够确保可预测且可靠的计划生育。除了可靠性之外，这类产品的市场也因配方的多样性而呈现多样化，有复方製剂和纯黄体素製剂可供选择，这反映了医生和消费者的偏好。此外，市场趋势取决于 OCP 与其他长期荷尔蒙结合避孕药相比的价格，以及基于 OCP 长期使用历史的记录便利性，儘管存在副作用，但 OCP 仍然是安全的。同时，该细分市场仍在不断发展，许多新的选择已经并将继续被开发，以减少副作用并提高荷尔蒙製剂的安全性和舒适度。整体而言，避孕OCP仍是全球女性生殖健康的前提。

荷尔蒙分手：

  • 仅含黄体素的避孕药
  • 合併荷尔蒙避孕药

复合激素避孕药占据产业最大份额

荷尔蒙类子市场以复方荷尔蒙避孕药 (CHC) 为主。此细分市场高份额的主要原因在于其极高的避孕功效和显着的健康益处。其益处包括：保证月经週期的持续时间和经期的舒缓，预防卵巢囊肿，以及显着降低子宫内膜癌的风险。 CHC 有药丸、阴道环和贴片等形式，为使用者提供了更方便的给药方式选择。因此，CHC 因其高度的灵活性和额外的健康益处，对广大用户来说是一个相当吸引人的选择。一些临床医生提到了一些担忧，例如情绪障碍的风险和体重增加的可能性。然而，CHC 的持续改进旨在降低这些副作用的风险，从而提高用户满意度和依从性。

按年龄组分类：

  • 15-24岁
  • 25-34岁
  • 35-44岁
  • 44岁以上

15-24 岁代表领先的细分市场

根据已确定的人口分布趋势和社会特征，15-24岁年龄层是荷尔蒙避孕药具使用者中最大的群体。这一年龄层通常指青春期晚期和成年早期，在这段时期，人们最积极地探索和利用避孕措施，并将其作为性健康和生殖健康管理的一部分。此外，青少年和年轻人性行为的增多，以及广泛的安全性行为教育计画（旨在倡导安全性行为并避免意外怀孕）的开展，也推动了这一年龄层的显着增长。因此，这也对荷尔蒙避孕药市场的统计数据产生了正面影响。教育机构、医疗保健提供者和社区组织特别关注这一年龄段，进行各种推广活动和咨询，使人们更容易获得有关不同避孕方法的资讯。同样，在组建家庭之前发展事业或完成学业的愿望也促使这些年轻人寻求充足、安全、可靠的避孕措施，这极大地促进了这一细分市场的强劲增长。

按最终用户分类：

  • 医院和诊所
  • 居家护理
  • 门诊手术中心
  • 其他的

家庭护理在市场上占据明显主导地位

荷尔蒙避孕市场的主要终端使用者是家庭护理领域，这得益于其提供的便利性和隐私性。鑑于当前消费者要求在家中舒适地做出医疗保健决策的趋势，对可自行管理的产品的需求必然会增长。避孕药具比以往任何时候都更容易取得，这进一步促进了这一趋势。例如，口服避孕药、透皮贴片和阴道环现在可以无需他人帮助地使用，并且在世界大部分地区都很容易买到。根据荷尔蒙避孕市场分析，许多线上平台和远距医疗服务使这些产品的取得变得简单，增强了在家中管理避孕需求的吸引力。此外，家庭照护趋势与以消费者为中心的医疗保健的整体发展相呼应，个人在满足自身健康需求方面寻求最佳的便利性、保密性和自主性。这些因素显着改变了荷尔蒙避孕市场的动态。

按地区划分：

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

北美引领市场，占据最大的荷尔蒙避孕市场份额

该报告还对所有主要区域市场进行了全面分析，包括北美（美国和加拿大）；亚太地区（中国、日本、印度、韩国、澳洲、印尼等）；欧洲（德国、法国、英国、义大利、西班牙、俄罗斯等）；拉丁美洲（巴西、墨西哥等）；以及中东和非洲。报告指出，北美是荷尔蒙避孕药最大的区域市场。

从地理上看，北美是全球领先的荷尔蒙避孕药市场，这得益于该地区完善的医疗基础设施、对避孕措施的高度认知以及政府的大力支持。此外，北美还有几家领先的製药公司正在投资开发更便利、有效和安全的避孕药。同时，美国人拥有最发达的健康文化，他们更倾向于提前「吞服」口服避孕药，而不是子宫内避孕环。此外，许多类型的避孕药都包含在保险范围内，包括政策性保险，这提高了可及性。公共和私人组织提供的众多教育计画也宣传了使用避孕药的好处。这种全面的支持确保了北美不仅是一个庞大的市场，而且是全球荷尔蒙避孕领域的领先地区。

竞争格局：

市场研究报告还对市场竞争格局进行了全面分析，并提供了所有主要公司的详细资料。荷尔蒙避孕产业的一些主要市场参与者包括：

  • Afaxys公司
  • Agile Therapeutics公司
  • 艾尔建公司（AbbVie Inc.）
  • 拜耳公司
  • 西普拉有限公司
  • 强生公司
  • 默克公司
  • 辉瑞公司
  • 皮拉马尔集团
  • 梯瓦製药工业股份有限公司

荷尔蒙避孕药市场的主要参与者致力于资助研究，并提升其产品的功效和安全性。他们不断减少副作用，提高用户便利性，以获得市场认可并保持品质领先地位。此外，包括拜耳公司、辉瑞公司和默克在内的公司希望透过在发展中国家的收购和联盟来扩大其全球影响力，因为这些国家目前对荷尔蒙避孕药的需求较高。此外，製造商经常推广荷尔蒙避孕药，并向更多女性宣传其相关优势。这些进展支持发展目标，同时也有助于实现更全面的公共卫生政策目标。

本报告回答的关键问题：

  • 全球荷尔蒙避孕市场迄今表现如何，未来几年将如何表现？
  • 全球荷尔蒙避孕市场的驱动因素、限制因素和机会是什么？
  • 每个驱动因素、限制因素和机会对全球荷尔蒙避孕市场有何影响？
  • 主要的区域市场有哪些？
  • 哪些国家代表最具吸引力的荷尔蒙避孕市场？
  • 根据产品，市场是如何分類的？
  • 荷尔蒙避孕市场上最具吸引力的产品是什么？
  • 基于荷尔蒙的市场区隔是怎样的？
  • 荷尔蒙避孕药市场上最吸引人的荷尔蒙是什么？
  • 根据年龄组，市场是如何分類的？
  • 荷尔蒙避孕市场上哪个年龄层的人最有吸引力？
  • 根据最终用户，市场是如何分類的？
  • 荷尔蒙避孕市场上最有吸引力的最终用户是谁？
  • 市场的竞争结构是怎么样的？
  • 全球荷尔蒙避孕市场的主要参与者/公司有哪些？

本报告回答的关键问题：

  • 全球荷尔蒙避孕市场迄今表现如何，未来几年将如何表现？
  • 全球荷尔蒙避孕市场的驱动因素、限制因素和机会是什么？
  • 每个驱动因素、限制因素和机会对全球荷尔蒙避孕市场有何影响？
  • 主要的区域市场有哪些？
  • 哪些国家代表最具吸引力的荷尔蒙避孕市场？
  • 根据产品，市场是如何分類的？
  • 荷尔蒙避孕市场上最具吸引力的产品是什么？
  • 基于荷尔蒙的市场区隔是怎样的？
  • 荷尔蒙避孕药市场上最吸引人的荷尔蒙是什么？
  • 根据年龄组，市场是如何分類的？
  • 荷尔蒙避孕市场上哪个年龄层的人最有吸引力？
  • 根据最终用户，市场是如何分類的？
  • 荷尔蒙避孕市场上最有吸引力的最终用户是谁？
  • 市场的竞争结构是怎么样的？
  • 全球荷尔蒙避孕市场的主要参与者/公司有哪些？

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 二手资料
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

第五章：全球荷尔蒙避孕市场

  • 市场概况
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场区隔：依产品

  • 口服避孕药
  • 子宫内避孕器（IUD）
  • 注射避孕药
  • 阴道环
  • 其他的

第七章：市场分化：荷尔蒙

  • 仅含黄体素的避孕药
  • 合併荷尔蒙避孕药

第八章：市场区隔：依年龄段

  • 15-24岁
  • 25-34岁
  • 35-44岁
  • 44岁以上

第九章：市场区隔：依最终用户

  • 医院和诊所
  • 居家护理
  • 门诊手术中心
  • 其他的

第十章：市场细分：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第 11 章：SWOT 分析

第 12 章：价值链分析

第 13 章：波特五力分析

第 14 章：价格分析

第 15 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Afaxys Inc.
    • Agile Therapeutics Inc.
    • Allergan Inc. (AbbVie Inc.)
    • Bayer AG
    • Cipla Limited
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Pfizer Inc.
    • Piramal Group
    • Teva Pharmaceutical Industries Ltd
Product Code: SR112025A4403

The global hormonal contraceptive market size reached USD 19.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 26.8 Billion by 2033, exhibiting a growth rate (CAGR) of 3.48% during 2025-2033. The market is experiencing steady growth driven by global awareness of reproductive health and family planning, the rising empowerment of women, particularly in developing regions, and the growing acceptance and use of contraceptives across the globe.

Hormonal Contraceptive Market Analysis:

  • Major Market Drivers: The demand for hormonal contraceptives is driven by family planning requirements and acceptance across the globe. The various governments and non-governmental organizations that solely try to reduce the rate of unplanned pregnancies are leading to the growth of this market.
  • Key Market Trends: According to the hormonal contraceptive market forecast, the recent trend that will have a major impact on this market is the increasing consumption of long-acting reversible contraceptives including IUDs and implants on account of being more effective and longer action period.
  • Geographical Trends: North America and Western Europe majorly lead in hormonal contraceptive usage due to high awareness levels, income, and healthcare facilities. On the contrary, Asia Pacific is anticipated to grow fastest due to urbanization, healthcare expenditure, and lifestyle factors.
  • Competitive Landscape: According to the hormonal contraceptive market research, the hormonal contraceptives market has several big pharmaceutical companies with extensive product portfolios and distribution networks. Both small and large companies are increasing their budgetary allocation to research and development (R&D) activities to develop new drugs with minimal side effects while maintaining consumer convenience.
  • Challenges and Opportunities: While the existence of cultural resistance and regulatory hurdles in various geographical areas constrain market growth, there remain multiple opportunities to invest in personalized contraceptive solutions and focus on unaddressed emerging markets with an increase in female employment.

Hormonal Contraceptive Market Trends:

Increasing global awareness and education on reproductive health

The extensive utilization of hormonal contraceptives on a global scale is largely dependent on increased awareness and education about reproductive health. Governments and relevant international organizations, such as the World Health Organization, continuously promote the concept and advantages of family planning through safe and effective contraceptive use. According to the World Health Organization, there were 1.9 billion women of reproductive age worldwide in 2021, 1.1 billion of whom need family planning. Of these, 874 million are using modern contraceptive methods, and there are 164 million women with an unmet need for contraception. Thus, this is significantly influencing the hormonal contraceptive market revenue. Specifically, extensive global campaigns target both women and men, informing them about their ability to control pregnancies and effective ways to reduce rapid population growth. Moreover, numerous educational programs targeting teens and young individuals have been rolled out to lay the groundwork for well-informed family planning decisions later in life. These educational initiatives are only effective when complemented by access to healthcare services and consultations that enable individuals to differentiate among various hormonal contraceptive methods. In this regard, comprehensive global educational and health programs are indispensable in ensuring these products are taken up in different regions.

Technological advancements and product innovation

The development of new and better hormonal contraceptive options that revolutionize the area also propels hormonal contraceptive market value. Recently, a novel ultra-low-dose preparation of 20 μg EE and 3 mg DRSP has been marketed in a 24/4 regimen (Yaz; Bayer AG). The efficacy is similar to, if not better than, older COCs, and the bleeding pattern is acceptable. Additionally, drug delivery system development is resulting in more reliable items that are simpler to manage and produce fewer side effects. Extended-cycle pills and improvements to intrauterine devices, such as fewer health hazards and a longer period of utilization, respectively, all address the increasing need for consumer convenience and lifestyle compatibility. In addition, such advancements enhance the consumer experience and compliance, resulting in an expanded market since women are more likely to use and resume contraceptive use. In addition, innovations in contraceptive product technologies take advantage of consumers' acquired interest and adoption and market choice to introduce more refined technologies. Therefore, this is creating a positive hormonal contraceptive market outlook.

Policy initiatives and funding for family planning

Policies, such as supportive government policies and increased funding for family planning programs, facilitate the hormonal contraceptive market growth. Several governments in various regions, particularly in developing countries, have passed policies to ensure that individuals have access to contraceptives as part of public health and women's empowerment measures. These policies lower the cost of contraceptives, make reproductive health services comprehensive and available to everyone, and incorporate contraceptive education in public health campaigns. Furthermore, global consortia and institutions offer funding to help underserved areas access reproductive health services. All these measures seek to reduce the cost and convince individuals to get contraceptives. Policies that guarantee easy and low-priced access to hormonal contraceptives help to meet public health needs and other socio-economic targets.

Hormonal Contraceptive Market Segmentation:

Breakup by Product:

  • Oral Contraceptive Pills
  • Intrauterine Device (IUD)
  • Injectable Birth Control
  • Vaginal Rings
  • Others

Oral contraceptive pills account for the majority of the hormonal contraceptive market share

Oral contraceptive pills (OCPs) continue to lead the hormonal contraceptive market as the largest product segment due to their unmatched combination of efficacy, convenience, and availability. The hormonal contraceptive market overview suggests that pills are the most common contraceptive method worldwide due to their safety, which secures predictable and reliable family planning. In addition to their reliability, the market for these products is diversified by the variability of formulations, with pills available in combined and progestin-only versions that reflect medical and consumer preferences. Moreover, the market tendency is determined by the price of OCPs in comparison with other long-term hormone-conjugated contraceptives, and the ease of documentation based on the long history of using OCPs that, despite the side effects, remain safe. In confluence with this, the segment is still developing, and many new options have been and continue to be developed to reduce the side effects and enhance the safety and comfort of hormonal formulations. Overall, contraceptive OCPs remain the premise of reproductive health for women worldwide.

Breakup by Hormone:

  • Progestin-only Contraceptive
  • Combined Hormonal Contraceptive

Combined hormonal contraceptive holds the largest share of the industry

The hormone sub-segment is dominated by combined hormonal contraceptives (CHCs). The main factor contributing to the segment's high share is their very high contraceptive efficacy combined with significant health benefits. Among the beneficial effects, it is worth mentioning the guaranteed duration of the menstrual cycle and the severity of menstruation, the prevention of ovarian cysts, and the significant reduction in the risk of endometrial cancer. CHCs are available in the form of pills, vaginal rings, and patches, giving users an additional choice of the form of administration that is most convenient for them. Thus, CHCs are an attractive option for a wide range of users due to their great flexibility and additional health benefits. Among the concerns, some clinicians mention the risk of mood disorders and the likelihood of weight gain. However, ongoing improvements aim to decrease the risk of these side effects, enhancing user satisfaction and adherence.

Breakup by Age Group:

  • 15-24 Years
  • 25-34 Years
  • 35-44 Years
  • Above 44 Years

15-24 years represents the leading market segment

The group of 15-24 years stands out as the largest segment of hormonal contraceptive users, based on identified trends in demographic distribution and social peculiarities. This age range usually refers to late adolescence and young adulthood, a period when individuals are most active in exploring and utilizing contraceptive options as part of their sexual and reproductive health management routines. In addition, the segment's considerable growth is driven by increased sexual activity among adolescents and young individuals, supported by broad educational programs that teach safe sex and promote the avoidance of unplanned pregnancies. Thus, this is also positively influencing the hormonal contraceptive market statistics. Educational institutions, healthcare providers, and community organizations pay special attention to this age group, conducting various outreach activities and consultations to make information about different methods of contraception more accessible. Similarly, the desire to build a career or complete education before starting a family also encourages these young individuals to seek adequate, secure, and reliable contraceptive options, contributing significantly to the strong representation of this submarket.

Breakup by End User:

  • Hospitals and Clinics
  • Homecare
  • Ambulatory Surgical Centers
  • Others

Homecare exhibits a clear dominance in the market

The leading end-user in the hormonal contraceptive market is the homecare segment, driven by the convenience and privacy it offers. Given the current trend of consumers demanding to make their healthcare decisions from the comfort of their homes, the demand for products that can be self-administered was bound to increase. This trend is further facilitated by the fact that contraceptives have become more attainable than ever before. Oral pills, transdermal patches, and vaginal rings, for example, can now be utilized without anyone's help and are readily available on the market in most parts of the world. According to the hormonal contraceptive market analysis, many online platforms and telehealth services make access to these products easy, enhancing the appeal of managing contraceptive needs at home. Furthermore, the homecare trend corresponds to the overall developments in consumer-centered healthcare, whereby individuals are seeking optimal levels of convenience, confidentiality, and autonomy in attending to their health needs. These factors have significantly altered the dynamics within the hormonal contraceptive market.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest hormonal contraceptive market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for hormonal contraceptive.

Geographically, North America is the leading market for hormonal contraceptives globally due to the region's well-developed healthcare infrastructure, high awareness about contraceptive types, and strong government support. There are also several leading pharmaceutical companies in North America investing in the development of more convenient, effective, and safe contraceptives. At the same time, Americans are the most developed in terms of the culture of taking care of their health and they prefer to "swallow" an oral agent in advance rather than an intrauterine spiral. Additionally, many types of contraceptives are covered by insurance, including under policies, which enhance accessibility. Numerous educational programs provided by public and private organizations also inform about the benefits of using contraceptives. This comprehensive support ensures that North America is not only a large market but also a leading region in the global hormonal contraceptive space.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the hormonal contraceptive industry include:

  • Afaxys Inc.
  • Agile Therapeutics Inc.
  • Allergan Inc. (AbbVie Inc.)
  • Bayer AG
  • Cipla Limited
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Piramal Group
  • Teva Pharmaceutical Industries Ltd.

The major players in the hormonal contraceptive market are committed to funding research and enhancing the efficacy and safety of their products. They consistently reduce side effects and increase user convenience to gain market acceptance and keep quality leadership. Furthermore, firms including Bayer AG, Pfizer, and Merck & Co. want to extend their global footprint through acquisitions and alliances in developing countries, where the hormonal contraceptive demand is currently higher. Additionally, manufacturers frequently promote hormonal contraception and educate more women about the advantages associated. These developments support development goals while aiding more comprehensive public health policy goals.

Key Questions Answered in This Report:

  • How has the global hormonal contraceptive market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global hormonal contraceptive market?
  • What is the impact of each driver, restraint, and opportunity on the global hormonal contraceptive market?
  • What are the key regional markets?
  • Which countries represent the most attractive hormonal contraceptive market?
  • What is the breakup of the market based on the product?
  • Which is the most attractive product in the hormonal contraceptive market?
  • What is the breakup of the market based on the hormone?
  • Which is the most attractive hormone in the hormonal contraceptive market?
  • What is the breakup of the market based on the age group?
  • Which is the most attractive age group in the hormonal contraceptive market?
  • What is the breakup of the market based on the end user?
  • Which is the most attractive end user in the hormonal contraceptive market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global hormonal contraceptive market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hormonal Contraceptive Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Oral Contraceptive Pills
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Intrauterine Device (IUD)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Injectable Birth Control
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Vaginal Rings
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Hormone

  • 7.1 Progestin-only Contraceptive
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Combined Hormonal Contraceptive
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Age Group

  • 8.1 15-24 Years
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 25-34 Years
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 35-44 Years
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Above 44 Years
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals and Clinics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Homecare
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Ambulatory Surgical Centers
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Afaxys Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
    • 15.3.2 Agile Therapeutics Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Allergan Inc. (AbbVie Inc.)
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 Bayer AG
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Cipla Limited
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Johnson & Johnson
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Merck & Co. Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Pfizer Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Piramal Group
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
    • 15.3.10 Teva Pharmaceutical Industries Ltd
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Hormonal Contraceptive Market: Major Drivers and Challenges
  • Figure 2: Global: Hormonal Contraceptive Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Hormonal Contraceptive Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Hormonal Contraceptive Market: Breakup by Product (in %), 2024
  • Figure 5: Global: Hormonal Contraceptive Market: Breakup by Hormone (in %), 2024
  • Figure 6: Global: Hormonal Contraceptive Market: Breakup by Age Group (in %), 2024
  • Figure 7: Global: Hormonal Contraceptive Market: Breakup by End User (in %), 2024
  • Figure 8: Global: Hormonal Contraceptive Market: Breakup by Region (in %), 2024
  • Figure 9: Global: Hormonal Contraceptive (Oral Contraceptive Pills) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Hormonal Contraceptive (Oral Contraceptive Pills) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Hormonal Contraceptive (Intrauterine Device-IUD) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Hormonal Contraceptive (Intrauterine Device-IUD) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Hormonal Contraceptive (Injectable Birth Control) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Hormonal Contraceptive (Injectable Birth Control) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Hormonal Contraceptive (Vaginal Rings) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Hormonal Contraceptive (Vaginal Rings) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Hormonal Contraceptive (Other Products) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Hormonal Contraceptive (Other Products) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Hormonal Contraceptive (Progestin-only Contraceptive) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Hormonal Contraceptive (Progestin-only Contraceptive) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Hormonal Contraceptive (Combined Hormonal Contraceptive) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Hormonal Contraceptive (Combined Hormonal Contraceptive) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Hormonal Contraceptive (15-24 Years) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Hormonal Contraceptive (15-24 Years) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Hormonal Contraceptive (25-34 Years) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Hormonal Contraceptive (25-34 Years) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Hormonal Contraceptive (35-44 Years) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Hormonal Contraceptive (35-44 Years) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Hormonal Contraceptive (Above 44 Years) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Hormonal Contraceptive (Above 44 Years) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Hormonal Contraceptive (Hospitals and Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Hormonal Contraceptive (Hospitals and Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Hormonal Contraceptive (Homecare) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Hormonal Contraceptive (Homecare) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Global: Hormonal Contraceptive (Ambulatory Surgical Centers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Global: Hormonal Contraceptive (Ambulatory Surgical Centers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Global: Hormonal Contraceptive (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Global: Hormonal Contraceptive (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: North America: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: North America: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: United States: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: United States: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: Canada: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: Canada: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Asia-Pacific: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Asia-Pacific: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: China: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: China: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Japan: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Japan: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: India: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: India: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: South Korea: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: South Korea: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Australia: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Australia: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Indonesia: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Indonesia: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Others: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Others: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Europe: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Europe: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Germany: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Germany: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: France: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: France: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: United Kingdom: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: United Kingdom: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Italy: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Italy: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Spain: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Spain: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Russia: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Russia: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Others: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Others: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Latin America: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Latin America: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Brazil: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: Brazil: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Mexico: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Mexico: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 83: Others: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 84: Others: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 85: Middle East and Africa: Hormonal Contraceptive Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 86: Middle East and Africa: Hormonal Contraceptive Market: Breakup by Country (in %), 2024
  • Figure 87: Middle East and Africa: Hormonal Contraceptive Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 88: Global: Hormonal Contraceptive Industry: SWOT Analysis
  • Figure 89: Global: Hormonal Contraceptive Industry: Value Chain Analysis
  • Figure 90: Global: Hormonal Contraceptive Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Hormonal Contraceptive Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Hormonal Contraceptive Market Forecast: Breakup by Product (in Million USD), 2025-2033
  • Table 3: Global: Hormonal Contraceptive Market Forecast: Breakup by Hormone (in Million USD), 2025-2033
  • Table 4: Global: Hormonal Contraceptive Market Forecast: Breakup by Age Group (in Million USD), 2025-2033
  • Table 5: Global: Hormonal Contraceptive Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 6: Global: Hormonal Contraceptive Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Hormonal Contraceptive Market: Competitive Structure
  • Table 8: Global: Hormonal Contraceptive Market: Key Players